Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 18Endocrine 7Sarcoma 3NET 3Head & Neck 1

Conditions

Neuroendocrine Tumors 3Parkinson Disease 2Neuroblastoma 2Congenital Hyperinsulinism 2Lewy Body Disease 1Brain Neoplasms 1

Interventions

lutetium Lu 177 dotatate 32Everolimus 19Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 12Temozolomide 12Nivolumab 11Capecitabine 10pembrolizumab 9lanreotide 9cabozantinib 8Positron Emission Tomography Computed Tomography 8177Lu-octreotide, DOTA(0)-Tyr(3)- 8Ga(III)-DOTATOC 73-Iodobenzylguanidine 7Somatostatin 6Octreotide 6Lutetium-177 6Carboplatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5surufatinib 5lenvatinib 5Ipilimumab 5Fluorodeoxyglucose F18 5pasireotide 4copper dotatate CU-64 4avelumab 4Single Photon Emission Computed Tomography Computed Tomography 4Positron-Emission Tomography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × fluorodopa F 18 × NET × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

University of Alberta

Phase 3 Completed
400 enrolled
CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

NCT02539433 2015-09-03

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

Northwell Health

Phase NA Completed
22 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡